(NASDAQ: PHAT) Phathom Pharmaceuticals's forecast annual revenue growth rate of 63.29% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.67%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.46%.
Phathom Pharmaceuticals's revenue in 2026 is $175,110,000.On average, 12 Wall Street analysts forecast PHAT's revenue for 2026 to be $26,440,907,812, with the lowest PHAT revenue forecast at $23,928,016,886, and the highest PHAT revenue forecast at $27,717,446,946. On average, 12 Wall Street analysts forecast PHAT's revenue for 2027 to be $42,256,597,297, with the lowest PHAT revenue forecast at $37,762,706,752, and the highest PHAT revenue forecast at $47,260,315,509.
In 2028, PHAT is forecast to generate $60,559,962,120 in revenue, with the lowest revenue forecast at $52,125,347,988 and the highest revenue forecast at $80,217,088,816.